A 67 year old man with recurrent hypotensive ventric• ular tachycardia, amiodarone-induced bradyarrhyth• mias and severe cardiac dysfunction underwent simul• taneous implantation of an automatic cardioverterl defibrillator and bipolar atrioventricular (A V) pace• maker. The pacing electrodes were placed epicardially near the right atrial appendage and on the lateral right ventricular wall. The rate detector of the automatic de• fibrillator was placed epicardially on the posterobasal Since the first report (1) in 1980 of successful automatic termination of life-threatening ventricular tachyarrhythmias by a surgically implanted device, the safety and efficacy of this form of treatment have been well documented, and the number of patients treated with the automatic implantable cardioverter/defibrillator (AleD, Intec Systems, Inc.) is rap• idly growing. The implantation of this device in a patient already wearing a permanent pulse generator may neces• sitate revision of the pacing leads to prevent the stimulation artifact from being sensed by the cardioverter/defibrillator and interfering with its function (2). This concern is par• ticularly relevant when the patient wears a dual chamber pulse generator or a unipolar single chamber unit. The recent availability of a bipolar dual chamber DDD pacemaker gave us the opportunity to evaluate the compatibility of this new pacing device with the automatic implantable cardioverter/ defi brillator.
A 67 year old man with recurrent hypotensive ventric• ular tachycardia, amiodarone-induced bradyarrhyth• mias and severe cardiac dysfunction underwent simul• taneous implantation of an automatic cardioverterl defibrillator and bipolar atrioventricular (A V) pace• maker. The pacing electrodes were placed epicardially near the right atrial appendage and on the lateral right ventricular wall. The rate detector of the automatic de• fibrillator was placed epicardially on the posterobasal Since the first report (1) in 1980 of successful automatic termination of life-threatening ventricular tachyarrhythmias by a surgically implanted device, the safety and efficacy of this form of treatment have been well documented, and the number of patients treated with the automatic implantable cardioverter/defibrillator (AleD, Intec Systems, Inc.) is rap• idly growing. The implantation of this device in a patient already wearing a permanent pulse generator may neces• sitate revision of the pacing leads to prevent the stimulation artifact from being sensed by the cardioverter/defibrillator and interfering with its function (2). This concern is par• ticularly relevant when the patient wears a dual chamber pulse generator or a unipolar single chamber unit. The recent availability of a bipolar dual chamber DDD pacemaker gave us the opportunity to evaluate the compatibility of this new pacing device with the automatic implantable cardioverter/ defi brillator.
Case Report
Clinical features. A 67 year old man with a history of myocardial infarction (1963 and 1978) had an episode of out-of-hospital cardiac arrest in January 1984 for which he left ventricular wall. Effective bipolar A V pacing produced no false counting of the heart rate by the automatic cardioverter/defibrillator, and ventricular tachycardia properly inhibited the pacemaker. Long-term follow-up study confirmed the safety -of this treatment. With proper precautions, bipolar A V pacing can be safely combined with an automatic cardioverter/defibrillator.
( Electrogram amplitude measured from the epicardial rate• counting electrodes was 21 m V, and that measured from the transcardiac spring-patch bipole was 11 mY. Electro• gram amplitude measured from the ventricular pacing bipole was 24 m V, and that measured from the atrial pacing bipole was 1.6 mY. The atrial pacing threshold was 2.3 V/4.9 rnA, and the ventricular pacing threshold was 0.8 V/I.3 rnA. The pacing leads were connected to the pulse generator (Medtronic Symbios, model 7006), which was temporarily programmed to an AOO mode at a rate of 70 beats/min, a pulse width of 0.5 ms and an output of 5 V. Further re• cordings obtained from the rate-sensing electrodes showed that atrial pacing produced no visible artifact. At the end of the procedure, cardioversionldefibrillation threshold mea• surements and successful testing of the unit (AID-B, rate cutoff 152.5 beats/min) were performed, and the chest was closed. The pulse generator was programmed to the AOO mode until the patient awakened, and was then repro• grammed to DDD pacing. Noninvasive, audible monitoring of the cardioverter/defibrillator function during AOO and A V sequential pacing confirmed that atrial pacing was not sensed by the unit and that ventricular activation was sensed as a single and only electrical event.
Postoperative hemodynamic measurements during dual chamber pacing showed a pulmonary capillary wedge pres• sure of less than 10 mm Hg and a cardiac index between 2.8 and 3.5 liters/min per m 2 . Because of postoperative respiratory complications the patient remained for 7 weeks under continuous cardiac monitoring during which appro• priate A V sequential pacing was consistently verified and no shock was recorded or reported by the patient.
Electropbysiologic study. Before his discharge from the hospital, the patient underwent another electrophysiologic study to measure the results of surgical treatment and to confirm the adequate function of the cardioverter/defibril• lator. During the first part of the procedure the unit was activated but inhibited with a magnet, to avoid its triggering by the stimulation program. Programmed stimulation of the right ventricular apex, including triple extrastimulation after trains of ventricular paced rhythm at cycle lengths as short as 400 ms, was unsuccessful in inducing sustained ventric• ular tachycardia. Instead, several episodes of nonsustained, monomorphous ventricular tachycardia with a cycle length of 370 ms were observed, the longest one lasting 27 seconds. During such episodes no inappropriate impulses origmating 
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_+-_ Automatic cardloverter defibnllator which delivered a synchronized shock 13.5 seconds after the onset of programmed stimulation, 11.5 seconds after the onset of ventricular tachycardia and 5.5 seconds after its spontaneous termination. The amiodarone blood level on the day of this procedure, 50 days after discontinuation of therapy, was 0.6 jLg/ml. The patient was discharged from the hospital the next day on a drug regimen including amiodarone, 200 mg/day. After a follow-up of 12 months he has experienced neither recurrence of ventricular tachycardia nor discharge from the cardioverterl defibrillator.
Discussion
Potential interference of the cardioverter/defibrilhitor by an implanted pacemaker. The rapidly growing use of automatic cardioversionldefibrillation for the long-term treatment of life-threatening ventricular arrhythmias is pre• senting implanting physicians with several new technical problems that may have important clinical consequences. Reports already published (2) indicate that one such prob• lem, namely, the coexisting need for long-term pacing and standby cardioversion/defibrillation, occurs in 5 to 10% of patients. Thus far, A V pacing could not be offered to those in need of automatic cardioversionldefibrillation because the unipolar pulses delivered by such pacemakers are known to interfere with the automatic device in two different fashions. The first and most common type of interference is an er• roneous and excessive counting of the heart rate by the cardioverter/defibrillator, which may interpret atrial pacing or ventricular pacing, or both, as electrical events separate from ventricular activation, leading to a doubling or tripling of the sensed heart rate and inappropriate discharges of the device (3). The second form of interference occurs when pacing is not properly inhibited and continues during ven• tricular tachycardia or fibrillation. This may alter the de• tection capability of the cardioverter/defibrillator which, at any given time, bases its arrhythmia analysis on the largest intracardiac electrical signals, in this instance those origi• nating from the pacing device. This results in failure of the automatic cardioverter/defibrillator to terminate the tachyarrhythmia.
Precautions to be observed with combined pacemaker and cardioverter/defihrillator implantation. From our observations it appears that the recent introduction of bipolar A V sequential pacemakers can offer a solution to the in• terference problem. However, precautions must be taken at the time of implantation to verify that even bipolar artifacts are not inappropriately sensed by the cardioverterl defibrillator. The electrodes should preferably be placed epicardially and as distant from each other as possible. The interelectrode spacing of the rate detector should be narrow, though one should keep in mind that the electrogram re-JACC Vol. 7, No. 4 April 1986:933-7 corded from it has to be at least 5 m V in amplitude to provide an adequate rate-counting signal. The rate detector signals should then be recorded and examined during atrial pacing to verify that no pacemaker artifact is present or large enough to confuse the rate counting by the cardioverter/defibrillator. In addition, proper counting of the heart rate by the auto• matic cardioverter/defibrillator can be verified noninvasively by magnet application, which should produce a single au• dible beep synchronized with each ventricular cycle. Ab• sence of inappropriate pacing should be established during an induced episode of ventricular tachycardia. Alternatively, it has been suggested that the proper detection function of the cardioverter/defibrillator be verified by the induction of ventricular tachycardia and fibrillation with the unit acti• vated and the pacemaker placed in asynchronous mode at maximal output (4) . Because of the different characteristics of the intracardiac signals generated by these two rhythms,
it is important that proper sensing be verified during induc• tion of both rhythms. Furthermore, if the patient is known to experience ventricular tachycardia of variable configu• ration, attempts should be made to verify proper detection of each configuration. In our patient, we decided against the induction of ventricular fibrillation because of his pre• carious cardiopulmonary reserve, and because all previously observed episodes of tachyarrhythmia, spontaneous or in• duced, were due to ventricular tachycardia and not fibril• lation. We recognize, however, that this was an incomplete evaluation. During testing of the cardioverter/defibrillator befote re• lease of the patient from the hospital, we observed its ac• tivation by a brief run of nonsustained ventricular tachy• cardia, with subsequent discharge duriIig sinus rhythm. This sequence of events has been documented by long-term car• diac monitoring during treatment with the cardioverterl defibrillator (5), and is a known cause of unexpected internal shocks in the conscious, asymptomatic state.
A new generation of automatic cardioverter/defibrillators that will have pacing capability is in the making. To the best of our knowledge, however, these new devices will provide only single chamber, ventricular pacing. Many can• didates for automatic cardioversionldefibrillation have se• verely impaired cardiac function and receive drugs that may produce chronic bradyarrhythmias; thus they are also in need of A V sequential pacing. Such patients will continue to pose the problem of pacemaker interference with the automatic cardioverterl defibrillator.
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